Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT03646123. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial will study two treatment combinations for classical Hodgkin lymphoma (cHL). This trial will find out if these two treatment combinations work to treat cHL. It will also find out what side effects occur. A side effect is anything the drug does besides treating cancer. This study will have three parts (Parts A, B, and C). The drugs used in Part A are a combination of targeted anticancer drug (brentuximab vedotin) and three chemotherapy drugs (doxorubicin, vinblastine, and dacarbazine). These four drugs are called "A+AVD." Participants will be treated with granulocyte colony stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of treatment (12 doses). Part A will look at whether the A+AVD drug combination reduces the number of participants who experience the side effect of febrile neutropenia. Febrile neutropenia is a very low white blood cell count and a fever, which can be life threatening. Parts B and C will use drug combination of brentuximab vedotin, plus nivolumab, doxorubicin, and dacarbazine. These four drugs are called "AN+AD." Parts B and C will study how well the drugs work to treat cHL and what side effects they cause.
Study identification
- NCT ID
- NCT03646123
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 255 participants
Conditions and interventions
Conditions
Interventions
- brentuximab vedotin Drug
- doxorubicin Drug
- vinblastine Drug
- dacarbazine Drug
- G-CSF Drug
- nivolumab Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 28, 2019 (Actual)
- Primary completion
- Nov 7, 2022 (Actual)
- Completion
- Aug 23, 2024 (Actual)
- Last update posted
- Aug 28, 2025
2019 – 2024
United States locations
- U.S. sites
- 55
- U.S. states
- 19
- U.S. cities
- 51
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Los Angeles Cancer Network / Compassionate Care Research Group | Fountain Valley | California | 92708 | — |
| Rocky Mountain Cancer Centers - Aurora | Aurora | Colorado | 80012 | — |
| University of Colorado Health Memorial Hospital | Colorado Springs | Colorado | 80909 | — |
| Cancer Centers of Colorado - Denver | Denver | Colorado | 80218 | — |
| Poudre Valley Health System (PVHS) | Fort Collins | Colorado | 80528 | — |
| SCL Health - St. Mary's Hospital & Medical Center | Grand Junction | Colorado | 81501 | — |
| Miami Cancer Institute at Baptist Health, Inc. | Miami | Florida | 33176 | — |
| Florida Cancer Specialists - North Region | St. Petersburg | Florida | 33705 | — |
| Cardinal Bernardin Cancer Center / Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Illinois Cancer Specialists | Niles | Illinois | 60714 | — |
| Illinois Cancer Care | Peoria | Illinois | 61615 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute / Wayne State University | Detroit | Michigan | 48201 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Minnesota Oncology Hematology P.A. | Edina | Minnesota | 55435 | — |
| Washington University in St Louis | St Louis | Missouri | 63110 | — |
| New Jersey Hematology Oncology Associates, LLC | Brick | New Jersey | 08724 | — |
| Regional Cancer Care Associates - Freehold | Freehold | New Jersey | 07728 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Regional Cancer Care Associates - Howell | Howell Township | New Jersey | 07731 | — |
| Morristown Medical Center/ Carol G. Simon Cancer Center | Morristown | New Jersey | 07960 | — |
| Regional Cancer Care Associates - Mount Holly | Mount Holly | New Jersey | 08060 | — |
| Regional Cancer Care Associates - Central Jersey | Somerville | New Jersey | 08876 | — |
| Regional Cancer Care Associates - Sparta | Sparta | New Jersey | 07871 | — |
| New York Oncology Hematology, P.C. | Albany | New York | 12208 | — |
| CareMount Medical Group | Mount Kisco | New York | 10549-3412 | — |
| Mount Sinai Medical Center | New York | New York | 10029 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Clinical Research Alliance - Abraham Mittelman, MD, LLC | Purchase | New York | 10577 | — |
| Clinical Research Alliance - Morton Coleman, MD | Westbury | New York | 11590 | — |
| Wake Forest Baptist Medical Center / Wake Forest University | Winston-Salem | North Carolina | 27157 | — |
| Oncology Hematology Care | Cincinnati | Ohio | 45242 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic, The | Cleveland | Ohio | 44195 | — |
| Toledo Clinic Cancer Center | Toledo | Ohio | 43623 | — |
| Willamette Valley Cancer Institute and Research Center | Eugene | Oregon | 97401 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Medical University of South Carolina/Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| University of Tennessee | Knoxville | Tennessee | 37920 | — |
| Tennessee Oncology-Nashville/Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Texas Oncology - Austin Midtown | Austin | Texas | 78705 | — |
| Texas Oncology - Medical City Dallas | Dallas | Texas | 75230 | — |
| Texas Oncology - Flower Mound | Flower Mound | Texas | 75028 | — |
| Brooke Army Medical Center | Fort Sam Houston | Texas | 78234 | — |
| Texas Oncology - Fort Worth 12th Avenue | Fort Worth | Texas | 76104 | — |
| MD Anderson Cancer Center / University of Texas | Houston | Texas | 77030-4095 | — |
| Texas Oncology - San Antonio Medical Center | San Antonio | Texas | 78240 | — |
| Texas Oncology - Northeast Texas | Tyler | Texas | 75702 | — |
| Huntsman Cancer Institute/University of Utah | Salt Lake City | Utah | 84112 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care | Salem | Virginia | 24153 | — |
| Kadlec Clinic Hematology and Oncology | Kennewick | Washington | 99336 | — |
| Vista Oncology Inc PS | Olympia | Washington | 98506 | — |
| Seattle Cancer Care Alliance / University of Washington | Seattle | Washington | 98109-1023 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03646123, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 28, 2025 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03646123 live on ClinicalTrials.gov.